15,550 Shares in Omeros Corporation $OMER Bought by International Assets Investment Management LLC

International Assets Investment Management LLC acquired a new position in shares of Omeros Corporation (NASDAQ:OMER) during the second quarter, HoldingsChannel reports. The firm acquired 15,550 shares of the biopharmaceutical company’s stock, valued at approximately $47,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in OMER. Wellington Management Group LLP acquired a new stake in shares of Omeros during the first quarter worth $1,118,000. Nuveen LLC acquired a new stake in shares of Omeros during the first quarter worth $938,000. Vanguard Group Inc. raised its holdings in shares of Omeros by 3.0% during the first quarter. Vanguard Group Inc. now owns 3,237,256 shares of the biopharmaceutical company’s stock worth $26,610,000 after acquiring an additional 95,599 shares during the period. Wealth Enhancement Advisory Services LLC bought a new position in Omeros in the first quarter valued at $579,000. Finally, Invesco Ltd. grew its position in Omeros by 169.1% in the first quarter. Invesco Ltd. now owns 87,044 shares of the biopharmaceutical company’s stock valued at $716,000 after purchasing an additional 54,696 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. HC Wainwright raised their target price on shares of Omeros from $9.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, October 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Omeros from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research report on Wednesday, October 15th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 target price on shares of Omeros in a research report on Wednesday, October 15th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Omeros currently has an average rating of “Moderate Buy” and an average target price of $27.50.

Omeros Price Performance

Shares of OMER opened at $7.55 on Friday. The firm has a 50-day moving average of $4.93 and a 200-day moving average of $4.58. Omeros Corporation has a one year low of $2.95 and a one year high of $13.60. The company has a market cap of $513.85 million, a PE ratio of -3.58 and a beta of 2.32.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.02. The firm had revenue of $28.60 million during the quarter, compared to the consensus estimate of $0.31 million. Analysts expect that Omeros Corporation will post -3.09 earnings per share for the current year.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.